Mechanism of pharmacogenetics on drug withdrawal

Abstract

Abstract: Drug safety, pharmacokinetics and pharmacodynamics are the most important indicators that determine whether the candidate compounds can can be developed into drugs. The listed drugs withdrawn from the market were often of serious adverse drugs reactions. Drugs in different individuals/groups may have different pharmacokinetics and pharmacodynamics, and even cause adverse drug reactions(ADR). While pharmacogenetics focuses on the influence of genetic factors on both. To clarify the mechanism of abnormal reactions caused by genetic variations, not only enhance drugs safety, with a more comprehensive description of the indications, but also could rewrite the fate of drugs to be withdrawn, which can make it better service to humanity.

Key words: Pharmacogenetics, Withdrawal, Genetic factors, Polymorphism, Adverse drug reactions

CLC Number:

CHEN Wang-qing, ZHANG Wei. Mechanism of pharmacogenetics on drug withdrawal[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1065-1071.

References

[1] Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies[J]. JAMA, 1998, 279(15): 1200- 1205.
[2] 孙忠实,朱珠. 当代药物不良反应的特点与对策(1)[J].中国医药导刊,2003,5(1):68-70.
[3] 郭晓昕,颜敏,张素敏,等. 对药品上市后安全性再评价若干问题的探讨[J]. 中国药学杂,2001,36(3): 205-208.
[4] Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA[J]. N Engl J Med,2004,351(17): 1707-1709.
[5] James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects[J]. N Engl J Med,2010,363(10): 905-917.
[6] Bae SK, Cao S, Seo KA, et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramineN-｛1-[1-(4-chlorophenyl)cyclobutyl] - 3-methylbutyl｝-N, N-dimethylamine) metabolites in human liver microsomes[J]. Drug Metab Dispos,2008,36(8): 1679-1688.
[7] Chung JY, Jang SB, Lee YJ, et al. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects[J]. J Clin Pharmacol,2011,51(1): 53-59.
[8] Hsiao DJ, Wu LS, Huang SY, et al. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene[J]. Pharmacogenet Genomics,2009,19(9): 730-733.
[9] 朱珠, 孙忠实. 阿洛司琼问市9个月即撤出市场[J]. 中国药学杂志,2001,36(3): 211.
[10] Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome[J]. Gastroenterology,2002,123(2): 425-432.
[11] Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hyroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome[J]. Gastroenterology,2006,130(1): 34-43.
[12] Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region[J]. Science,1996,274(5292): 1527-1531.
[13] Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines[J]. Clin Allergy Immunol,2002,17: 389-419.
[14] Zhou Z, Vorperian VR, Gong Q, et al. Block of HERG potassinm channels by the anfihistamine astemizole and its metabolites desmethylastemizole and norastemizole[J]. Cardiovasc Electrophysiol,1999,10(6): 836-843.
[15] Matsumoto S, Hirama T, Kim HJ, et al. Involvement of cyp2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole[J]. Drug Metab Dispos,2002,30(11): 1240-1245.
[16] Matsumoto S, Hirama T, Kim HJ, et al. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver[J]. Xenobiotica,2003,33(6): 615-623.
[17] Lee SS, Jeong HE, Liu KH,et al. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity[J]. Pharmacogenet Genomics,2005,15(2): 105-113.
[18] Yamazaki H, Okayama A, Imai N, et al. Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations[J]. Xenobiotica,2006,36(12): 1201-1209.
[19] Ficker E, Obejero-Paz CA, Zhao S, et al. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene(HERG) mutations[J]. J Biol Chem, 2002,277(7):4989-4998.
[20] Gussak I, Antzelevitch C, Wilde AAM,et al. Electrical Diseases of the Heart[M]. New York: Springerlink press,2008:Part V, 677-690.
[21] Mück W. Clinical pharmacokinetics of cerivastatin[J]. Clin Pharmacokinet,2000,39(2): 99-116.
[22] Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis[J]. N Engl J Med,2002,346(7): 539-540.
[23] Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance[J]. Clin Pharmacol Ther,2006,80(6): 565-581.
[24] Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes regulatory region[J]. Drug Metab Dispos,2002,30(11): 1280-1287.
[25] Kameyama Y, Yamashita K, Kobayashi K,et al. Functional characterization of SLCO1B1(OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells[J]. Pharmacogenet Genomics, 2005,15(7): 513-522.
[26] Ishikawa C, Ozaki H, Nakajima T, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin[J]. J Hum Genet,2004, 49(10): 582-585.
[27] Maclennan S, Augood C, Cash-Gibson L, et al. Cisapride treatment for gastro-oesophageal reflux in children[J]. Cochrane Database Syst Rev,2010, 4: CD002300.
[28] Michalets EL, Williams CR. Drug interactions with cisapride clinical implications[J]. Clin Pharmacokinet,2000,39(1): 49-75.
[29] Wang SH, Lin CY, Huang TY, et al. QT interval effects of cisapride in the clinical setting[J]. Int J Cardiol,2001,80(2/3): 179-183.
[30] Cools F, Benatar A, Bougatef A, et al. The effect of cisapride on the corrected QT interval and QT dispersion in premature infants[J]. J Pediatr Gastroenterol Nutr,2001,33(2): 178-181.
[31] Lowry JA, Kearns GL, Abdel-Rahman SM, et al. Cisapride: A potential model substrate toassess cytochrome P4503A4 activity in vivo[J].Clin Pharmacol Ther,2003,73(3): 209-222.
[32] Yang P, Kanki H, Drolet B,et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes[J]. Circulation,2002,105(16): 1943-1948.
[33] Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias[J]. J Cardiovasc Electrophysiol,2000,11(6): 691-696.
[34] Finley MR, Li Y, Hua F, et al. Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart[J]. Am J Physiol Heart Circ Physiol,2002,283(1): H126-138.
[35] Lees-Miller JP, Duan Y, Teng GQ, et al. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites[J]. Mol Pharmacol,2000,57(2): 367-374.
[36] Food and Drug Administration, U.S. Department of Health and Human Services.Janssen Pharmaceutica stops marketing cisapride in the US[EB/OL]. T00-14, March 23, 2000.http: www.fda.gov bbs topics ANSWERS ANS01007.html.
[37] Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation[J]. Circulation,2002,106(10): 1269- 1274.
[38] Liu K, Yang T, Viswanathan PC, et al. New mechanism contributing to drug-induced arrhythmiarescue of a misprocessed LQT3 mutant[J]. Circulation,2005, 112(21): 3239-3246.
[39] Elangbam CS. Current strategies in the development of anti-obesity drugs and their safety concerns[J]. Vet Pathol,2009,46(1): 10-24.
[40] Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group[J]. N Engl J Med,1996,335(9): 609-616.
[41] 杨景勋.芬氟拉明和右芬氟拉明的下市及其不良反应[J].药物不良反应杂志,1999,1(1): 14-17.
[42] Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives[J]. Eur Respir J,2002,20(3): 518-523.
[43] Morse JH. Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension[J]. Chest,2002,121(3 Suppl): S50-S53.
[44] Blanpain C, Le Poul E, Parma J, et al. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine associated primary pulmonary hypertension[J]. Cardiovasc Res, 2003,60(3):518-528.
[45] Gross AS, Phillips AC, Rieutord A, et al. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine[J]. Br J Clin Pharmacol,1996,41(4):311-317.
[46] Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis[J]. Lancet,2004,364(9450): 2021-2029.
[47] Department of Health and Ageing. Consumer level recall of arthritis drug[R]. Available from URL: http: //www.tga.gov.au/media/2004/040930vioxx.htm. 2004.
[48] Zhang JY, Zhan J, Cook CS, et al. Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism[J]. Drug Metab Dispos,2003,31(5): 652-658.
[49] Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib a specific cyclo-oxygenase-2 inhibitor[J]. Clin Pharmacokinet, 2003,42(6): 545-556.
[50] St Germaine CG, Bogaty P, Boyer L, et al. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-infl ammatory drugs[J]. Am J Cardiol,2010,105(12): 1740-1745.
[51] Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular disease by a dysfunctional rostacyclin receptor mutation potential implications for cyclooxygenase-2 inhibition[J]. Circ Res,2008,102(8): 986-993.
[52] Sertindole: new drug. Another “atypical” neuroleptic; QT prolongation[J]. Prescrire Int,2007, 16(88): 59-62.
[53] Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review[J]. Basic Clin Pharmacol Toxicol,2007, 100(1): 4-22.
[54] Wong SL, Menacherry S, Mulford D, et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function[J]. Eur J Clin Pharmacol, 1997,52(3): 223-227.
[55] Rampe D, Murawsky MK, Grau J, et al. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG[J]. J Pharmacol Exp Ther,1998,286(2): 788-793.
[56] Kang J, Chen XL, Rampe D. The Antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+)channel[J]. Biochem Biophys Res Commun,2001, 286(3): 499-504.
[57] Hartigan-Go K, Bateman DN, Daly AK, et al. Stereoselective cardiotoxic effects of terodiline[J]. Clin Pharmacol Ther,1996,60(1): 89-98.
[58] Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system[J]. Br J Clin Pharmacol,2000,50(1): 77-80.
[59] Martin RL, Su Z, Limberis JT, et al. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience[J]. J Cardiovasc Pharmacol, 2006,48(5): 199-206.
[60] Thomas SH, Higham PD, Hartigan-Go K, et al. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence[J]. Br Heart J,1995,74(1):53-56.
[61] Paakkari I. Cardiotoxicity of new antihistamines and cisapride[J]. Toxicol Lett,2002,127(1/2/3): 279-284.
[62] Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels[J]. Proc Natl Acad Sci USA,2002,99(19): 12461-12466.
[63] 杨剑,缪丽燕. 华法林的基因组学研究进展[J]. 中国临床药理学与治疗学,2006,11(12): 1326-1331.
[64] Hung Si, Chung Wh, Jee Sh, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions[J]. Pharmacogenet Genomics,2006,16(4): 297-306.
[65] 魏伟.对临床药理学一些基本问题研究的思考[J]. 中国临床药理学与治疗学,2008,13(10): 1081-1085.